Serologicals' Upstate Group Sponsors Second Annual Cell Signalling Symposium June 12-15, 2005.

ATLANTA -- Serologicals Corporation (NASDAQ: SERO) today announced that Upstate Group, its wholly owned subsidiary, is sponsoring the Second Annual Cell Signalling Symposium to be held June 12-15, 2005, at the Apex City Quay Hotel, Dundee, U.K. It is co-sponsored by Upstate and the MRC Protein Phosphorylation Unit at the University of Dundee. This two-and-a-half day, not-for-profit meeting is entitled 'Implications of the LKB1 and AMPK Systems.' Registration is open to all scientists with an interest in cell signaling, drug discovery and disease.

The keynote lecture will be held on Sunday evening, June 12, by Tony Pawson from the Samuel Lumenfeld Research Institute, Toronto, Canada on the topic of Cell Polarity. The keynote will be followed by an Account of the Discovery of LKB1 by Lauri Aaltonen from the University of Helsinki, Finland. Other featured speakers include Dario Alessi and other scientists from the University of Dundee; Imperial College, London; Harvard Institute of Medicine, Boston; August Krogh Institute, Copenhagen; Stanford University School of Medicine, and others. Topics featured will include: Structure and Regulation of AMPK; Physiology of AMPK in Muscle and Diabetes; LKB1 Regulation of AMPK and mTOR; LKB1 and Novel Treatments for Peutz Jeghers Syndrome; LKB1 and the MARK Kinases in Drosophila.

Also at the symposium, the winner of the Upstate Young Cell Signaller 2005 Award will be announced from five finalists chosen from Ph.D. students and first time post-doctorates who are encouraged to submit abstracts to an experienced scientific panel for judging. The winner will receive $17,000 (EUR 14,000) worth of support funding for reagents for their laboratory, a personal cash prize of $8,500 (EUR 7000) and a trophy.

To find out more about the symposium or to register, visit www.upstate.com/symposia/2005, or call [phone] or e-mail [e-mail].

Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market. Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology. Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, g-proteins and cytokines, Upstate's advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits, multiplex assays are used by thousands of customers worldwide, every day to accelerate improving human health. Upstate, a Serologicals company, is headquartered in Charlottesville, VA, with locations in Lake Placid, NY, and Dundee, Scotland.

For more information, please visit our website www.upstate.com.

Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry.

Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.

For more information, please visit our website: www.serologicals.com.

Serologicals is a registered trademark of Serologicals Royalty Company.